These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 25943030)

  • 1. Minimally invasive (13)C-breath test to examine phenylalanine metabolism in children with phenylketonuria.
    Turki A; Murthy G; Ueda K; Cheng B; Giezen A; Stockler-Ipsiroglu S; Elango R
    Mol Genet Metab; 2015; 115(2-3):78-83. PubMed ID: 25943030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo studies of phenylalanine hydroxylase by phenylalanine breath test: diagnosis of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.
    Okano Y; Hase Y; Kawajiri M; Nishi Y; Inui K; Sakai N; Tanaka Y; Takatori K; Kajiwara M; Yamano T
    Pediatr Res; 2004 Nov; 56(5):714-9. PubMed ID: 15319459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients.
    Utz JR; Lorentz CP; Markowitz D; Rudser KD; Diethelm-Okita B; Erickson D; Whitley CB
    Mol Genet Metab; 2012 Feb; 105(2):193-7. PubMed ID: 22112818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sapropterin dihydrochloride: a new drug and a new concept in the management of phenylketonuria.
    Trefz FK; Belanger-Quintana A
    Drugs Today (Barc); 2010 Aug; 46(8):589-600. PubMed ID: 20830319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).
    Winn SR; Scherer T; Thöny B; Harding CO
    Mol Genet Metab; 2016 Jan; 117(1):5-11. PubMed ID: 26653793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study.
    Burton BK; Nowacka M; Hennermann JB; Lipson M; Grange DK; Chakrapani A; Trefz F; Dorenbaum A; Imperiale M; Kim SS; Fernhoff PM
    Mol Genet Metab; 2011 Aug; 103(4):315-22. PubMed ID: 21646032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial.
    Muntau AC; Burlina A; Eyskens F; Freisinger P; De Laet C; Leuzzi V; Rutsch F; Sivri HS; Vijay S; Bal MO; Gramer G; Pazdírková R; Cleary M; Lotz-Havla AS; Munafo A; Mould DR; Moreau-Stucker F; Rogoff D
    Orphanet J Rare Dis; 2017 Mar; 12(1):47. PubMed ID: 28274234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unresponsiveness to tetrahydrobiopterin of phenylalanine hydroxylase deficiency.
    Ponzone A; Porta F; Mussa A; Alluto A; Ferraris S; Spada M
    Metabolism; 2010 May; 59(5):645-52. PubMed ID: 19913839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tetrahydrobiopterin and phenylalanine on in vivo human phenylalanine hydroxylase by phenylalanine breath test.
    Okano Y; Takatori K; Kudo S; Sakaguchi T; Asada M; Kajiwara M; Yamano T
    Mol Genet Metab; 2007 Dec; 92(4):308-14. PubMed ID: 17884650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU).
    Burton BK; Bausell H; Katz R; Laduca H; Sullivan C
    Mol Genet Metab; 2010; 101(2-3):110-4. PubMed ID: 20638313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wild-type phenylalanine hydroxylase activity is enhanced by tetrahydrobiopterin supplementation in vivo: an implication for therapeutic basis of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.
    Kure S; Sato K; Fujii K; Aoki Y; Suzuki Y; Kato S; Matsubara Y
    Mol Genet Metab; 2004; 83(1-2):150-6. PubMed ID: 15464429
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Teraishi T; Kajiwara M; Hori H; Sasayama D; Hidese S; Matsuo J; Ishida I; Kajiwara Y; Ozeki Y; Ota M; Hattori K; Higuchi T; Kunugi H
    J Psychiatr Res; 2018 Apr; 99():142-150. PubMed ID: 29454221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sapropterin dihydrochloride for the treatment of hyperphenylalaninemias.
    Blau N
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1207-18. PubMed ID: 23705856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into tetrahydrobiopterin pharmacodynamics from Pah enu1/2, a mouse model for compound heterozygous tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.
    Lagler FB; Gersting SW; Zsifkovits C; Steinbacher A; Eichinger A; Danecka MK; Staudigl M; Fingerhut R; Glossmann H; Muntau AC
    Biochem Pharmacol; 2010 Nov; 80(10):1563-71. PubMed ID: 20705059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.
    Sanford M; Keating GM
    Drugs; 2009; 69(4):461-76. PubMed ID: 19323589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Open, non-comparative phase III clinical study to evaluate the efficacy and safety of sapropterin in patients with phenylketonuria and hyperphenylalaninemia].
    Bushueva TV; Kuzenkova LM; Borovik TÉ; Nazarenko LP; Seitova GN; Filimonova MN; Pichkur NA; Samonenko NV; Shkurko TA; Akhmadeeva ÉN; Mardanova AK; Garifullina ÉR; Kovtun OP; Bazhenova IuL; Alimova IL; Kostiakova EA; Minaĭcheva LI; Saliukova OA; Sivokha VM; Rozenson OL
    Vestn Ross Akad Med Nauk; 2014; (7-8):69-77. PubMed ID: 25563006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to tetrahydrobiopterin therapy in patients with phenylketonuria.
    Rohr F; Wessel A; Brown M; Charette K; Levy HL
    Mol Genet Metab; 2015 Jan; 114(1):25-8. PubMed ID: 25467057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sapropterin dihydrochloride in patients with phenylketonuria: A meta-analysis of randomized controlled trials.
    Qu J; Yang T; Wang E; Li M; Chen C; Ma L; Zhou Y; Cui Y
    Br J Clin Pharmacol; 2019 May; 85(5):893-899. PubMed ID: 30720885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria.
    Blau N; Bélanger-Quintana A; Demirkol M; Feillet F; Giovannini M; MacDonald A; Trefz FK; van Spronsen FJ
    Mol Genet Metab; 2009 Apr; 96(4):158-63. PubMed ID: 19208488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on sapropterin in primary hyperphenylalaninemia.
    Sanford M; Keating GM
    BioDrugs; 2009; 23(3):201-2. PubMed ID: 19627172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.